Basit öğe kaydını göster

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

dc.contributor.authorDore, G. J.
dc.contributor.authorMoreno, C.
dc.contributor.authorMurphy, K.
dc.contributor.authorNegro, F.
dc.contributor.authorNemecek, V.
dc.contributor.authorOrmeci, N.
dc.contributor.authorOvrehus, A. L. H.
dc.contributor.authorParkes, J.
dc.contributor.authorPasini, K.
dc.contributor.authorPeltekian, K. M.
dc.contributor.authorRamji, A.
dc.contributor.authorReis, N.
dc.contributor.authorRoberts, S. K.
dc.contributor.authorRosenberg, W. M.
dc.contributor.authorRoudot-Thoraval, F.
dc.contributor.authorRyder, S. D.
dc.contributor.authorSarmento-Castro, R.
dc.contributor.authorSemela, D.
dc.contributor.authorSherman, M.
dc.contributor.authorShiha, G. E.
dc.contributor.authorSievert, W.
dc.contributor.authorSperl, J.
dc.contributor.authorStarkel, P.
dc.contributor.authorStauber, R. E.
dc.contributor.authorThompson, A. J.
dc.contributor.authorUrbanek, P.
dc.contributor.authorVan Damme, P.
dc.contributor.authorvan Thiel, I.
dc.contributor.authorVan Vlierberghe, H.
dc.contributor.authorVandijck, D.
dc.contributor.authorWedemeyer, H.
dc.contributor.authorWeis, N.
dc.contributor.authorWiegand, J.
dc.contributor.authorYosry, A.
dc.contributor.authorZekry, A.
dc.contributor.authorCornberg, M.
dc.contributor.authorMuellhaupt, B.
dc.contributor.authorEstes, C.
dc.contributor.authorKaymakoglu, S.
dc.contributor.authorRazavi, H.
dc.contributor.authorWaked, I.
dc.contributor.authorSarrazin, C.
dc.contributor.authorMyers, R. P.
dc.contributor.authorIdilman, R.
dc.contributor.authorCalinas, F.
dc.contributor.authorVogel, W.
dc.contributor.authorMendes Correa, M. C.
dc.contributor.authorHezode, C.
dc.contributor.authorLazaro, P.
dc.contributor.authorAkarca, U.
dc.contributor.authorAleman, S.
dc.contributor.authorBalik, I.
dc.contributor.authorBerg, T.
dc.contributor.authorBihl, F.
dc.contributor.authorBilodeau, M.
dc.contributor.authorBlasco, A. J.
dc.contributor.authorBrandao Mello, C. E.
dc.contributor.authorBruggmann, P.
dc.contributor.authorButi, M.
dc.contributor.authorCalleja, J. L.
dc.contributor.authorCheinquer, H.
dc.contributor.authorChristensen, P. B.
dc.contributor.authorClausen, M.
dc.contributor.authorCoelho, H. S. M.
dc.contributor.authorCramp, M. E.
dc.contributor.authorDoss, W.
dc.contributor.authorDuberg, A. S.
dc.contributor.authorEl-Sayed, M. H.
dc.contributor.authorErgor, G.
dc.contributor.authorEsmat, G.
dc.contributor.authorFalconer, K.
dc.contributor.authorFelix, J.
dc.contributor.authorFerraz, M. L. G.
dc.contributor.authorFerreira, P. R.
dc.contributor.authorFrankova, S.
dc.contributor.authorGarcia-Samaniego, J.
dc.contributor.authorGerstoft, J.
dc.contributor.authorGiria, J. A.
dc.contributor.authorGoncales, F. L.
dc.contributor.authorGower, E.
dc.contributor.authorGschwantler, M.
dc.contributor.authorGuimaraes Pessoa, M.
dc.contributor.authorHindman, S. J.
dc.contributor.authorHofer, H.
dc.contributor.authorHusa, P.
dc.contributor.authorKaberg, M.
dc.contributor.authorKaita, K. D. E.
dc.contributor.authorKautz, A.
dc.contributor.authorKrajden, M.
dc.contributor.authorKrarup, H.
dc.contributor.authorLaleman, W.
dc.contributor.authorLavanchy, D.
dc.contributor.authorMarinho, R. T.
dc.contributor.authorMarotta, P.
dc.contributor.authorMauss, S.
dc.date.accessioned2021-03-03T08:24:11Z
dc.date.available2021-03-03T08:24:11Z
dc.identifier.citationRazavi H., Waked I., Sarrazin C., Myers R. P. , Idilman R., Calinas F., Vogel W., Mendes Correa M. C. , Hezode C., Lazaro P., et al., "The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm", JOURNAL OF VIRAL HEPATITIS, cilt.21, ss.34-59, 2014
dc.identifier.issn1352-0504
dc.identifier.othervv_1032021
dc.identifier.otherav_1755e66f-884b-4569-88d4-daa1549a0c4d
dc.identifier.urihttp://hdl.handle.net/20.500.12627/21052
dc.identifier.urihttps://doi.org/10.1111/jvh.12248
dc.description.abstractThe disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectGastroenteroloji-(Hepatoloji)
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectVİROLOJİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMikrobiyoloji ve Klinik Mikrobiyoloji
dc.subjectViroloji
dc.subjectDahili Tıp Bilimleri
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.titleThe present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
dc.typeMakale
dc.relation.journalJOURNAL OF VIRAL HEPATITIS
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume21
dc.identifier.startpage34
dc.identifier.endpage59
dc.contributor.firstauthorID214819


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster